Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial

Lancet

Volumn 359, Issue 9313, 2002, Pages 1187-1193

  Braun, J ^a,b,l   Brandt, J ^a   Listing, J ^c   Zink, A ^c   Alten, R ^d   Golder, W ^a   Gromnica Ihle, E ^f   Kellner, H ^g   Krause, A ^e   Schneider, M ^h   Sorensen H ⁱ   Zeidler, H ^j   Thriene, W ^k   Sieper, J ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Centre of Rheumatology Ruhrgebiet   (Germany)

^c German Rheumatism Research Centre   (Germany)

^d Schlosspark Clinic   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f Clinic of Rheumatology   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ Immanuel Hospital   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k Essex Pharma   (Germany)

^l RHEUMAZENTRUM RUHRGEBIET   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SPINE RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS; VALIDATION PROCESS;

EID: 0037029430     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08215-6     Document Type: Article

References (36)

1. Prevalence of spondylarthropathies in HLA B27-positive and negative blood donors
2. Update: The twenty subtypes of HLA-B27
3. Pathogenesis of Spondylarthropathies: Persistent bacterial antigen, autoimmunity, or both?
4. Enthesitis and ankylosis in spondyloarthropathy: What is the target of the immune response?
5. Radiologic diagnosis and pathology of the spondyloarthropathies
6. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - Results from the German rheumatological database
7. Employment, work disability, and work days lost in patients with ankylosing spondylitis: A cross sectional study of Dutch patients
8. Prognosis, course of disease, and treatment of the spondyloarthropathies
9. Quality of life in patients with ankylosis spondylitis: A survey of 175 patients
10. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
11. Anti-tumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety
12. Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms
13. Successful treatment of severe psoriatic arthritis with infliximab
14. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
15. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
16. Infliximab and methotrexate in the treatment of rheumatoid arthritis
17. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
18. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
19. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria
20. A new approach to defining disease status in ankylosing spondylitis. The Bath ankylosing spondylitis disease activity index
21. Preliminary core sets for endpoints in ankylosing spondylitis
22. A new approach to defining functional ability in ankylosing spondylitis. The Bath ankylosing spondylitis functional index
23. Defining spinal mobility in ankylosing spondylitis. The Bath ankylosing spondylitis metrology index
24. ASAS preliminary criteria for short term improvement in ankylosing spondylitis
25. The MOS 36-item short-form health survey (SF 36). Conceptual framework and item selection
26. The Bath ankylosing spondylitis radiology index (BASRI)
27. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug
28. A simple sequentially rejective multiple test procedure
29. Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab
30. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis
31. Fatigue in ankylosing spondylitis: Its prevalence and relationship to disease activity, sleep, and other factors
32. Treatment of patients with severe ankylosing spondylitis with infliximab - A one year follow up
33. Radiological scoring methods in ankylosing spondylitis: Reliability and sensitivity to change over one year
34. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients
35. Tuberculosis Associated with Infliximab, a tumor necrosis factor-neutralizing agent